arrow
E

Elizabeth D. Kantor

memorial sloan kettering cancer center
H指数:26
被引数:4,051

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settings

对识别真实世界环境中化疗相关血液学毒性的方法进行评估

2025-11-010
PRE
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer

年龄与Ⅰ期-ⅢA期乳腺癌女性化疗剂量减量的关联

2025-11-010
PRE
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer

了解身体质量指数与接受I-IIIA期乳腺癌治疗女性化疗剂量减少之间的关联

2025-10-290
OA
Patient characteristics associated with conventional schedule vs. dose dense chemotherapy in women with stage I–IIIA breast cancer

与常规方案相比,剂量密集化疗在I~IIIA期乳腺癌女性患者中的相关患者特征

2025-07-060
PRE
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study
2025-02-010
PRE
The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system

在综合医疗保健提供系统中,在i-iiia期乳腺癌中使用NCCN指南化疗方案的前景

2024-08-160
PRE
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast Cancer
2024-07-251
PRE
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer
2024-07-060
PRE
Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019
2024-06-131
OAAI
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer
2024-04-014
PRE
A methodology for using real-world data from electronic health records to assess chemotherapy administration in women with breast cancer
2023-03-010
PRE